home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

7.540 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Verastem, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

March 14, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

March 11, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

March 05, 2024

From Verastem Oncology

Via Business Wire

Where Verastem Stands With Analysts ↗

November 15, 2023

Via Benzinga

Analyst Ratings for Verastem ↗

September 27, 2023

Via Benzinga

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024

March 05, 2024

From Verastem Oncology

Via Business Wire

Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

February 12, 2024

Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and...

Via Benzinga

3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024 ↗

February 07, 2024

Discover AI's top stock selections, meticulously analyzed for 2024, promising more than just returns but a revolution in your portfolio.

Via InvestorPlace

Topics Artificial Intelligence

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers

January 29, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

January 18, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference

January 11, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 05, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics

December 18, 2023

From Verastem Oncology

Via Business Wire

3 Off-the-Beaten-Path Stocks Poised for Substantial Growth ↗

December 13, 2023

Although there’s safety in numbers, many times, you need to consider uncommon stocks to buy for growth for robust upside.

Via InvestorPlace

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

December 13, 2023

From Verastem Oncology

Via Business Wire

Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential ↗

December 03, 2023

Although even so-called penny stocks with potential carry dramatic risks, these four-baggers benefit from analyst backing.

Via InvestorPlace

New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach

November 13, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

November 08, 2023

From Verastem Oncology

Via Business Wire

First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer

November 07, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population

November 06, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Strengthens Executive Leadership Team with Key Appointments

October 26, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 18, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer

October 14, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 06, 2023

From Verastem Oncology

Via Business Wire

Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit

September 28, 2023

From Verastem Oncology

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023 ↗

September 27, 2023

Via Benzinga

Verastem Oncology to Participate in Upcoming Investor Conferences

September 05, 2023

From Verastem Oncology

Via Business Wire

3 Penny Stocks That Can Triple Your Money in the Next 12 Months ↗

September 04, 2023

Although penny stocks are among the most speculative asset classes, these wagers just happen to have strong analyst backing.

Via InvestorPlace

Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal ↗

September 02, 2023

Shanghai GenFleet Technologies partnered three preclinical small-molecule candidates for RAS pathway-driven cancers to Verastem Oncology in a deal that could be worth up to $625.5 million. GenFleet...

Via Talk Markets

Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers

August 28, 2023

From Verastem Oncology

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com